Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jorge Romaguera, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1987 - 1988
University of Puerto RicoFellowship, Hematology and Medical Oncology, 1985 - 1987- University of Puerto RicoResidency, Internal Medicine, 1982 - 1985
- University of Puerto Rico School of MedicineClass of 1982
Certifications & Licensure
TX State Medical License 1988 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 28 citationsPre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphomaPaolo Strati, Mohamed Amin Ahmed, Nathan Fowler, Loretta J. Nastoupil, Felipe Samaniego
Haematologica. 2020-07-01 - 57 citationsEfficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patientsShuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, Chi Young Ok, Shaojun Zhang
American Journal of Hematology. 2020-06-01 - 43 citationsGenomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.Preetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, Chi Young Ok, Krystle Nomie
Blood Advances. 2020-03-24
Press Mentions
Non-Hodgkin’s Lymphoma Survivor Grateful for Fertility PreservationAugust 30th, 2018
Adding Bortezomib Does Not Improve MCL OutcomesMay 16th, 2018
Ibrutinib Has 'Unprecedented' Impact on Mantle Cell LymphomaDecember 14th, 2012- Join now to see all
